FDA approves Pfizer Nivestym, second Neupogen biosimilar

By Allison Johnson | Jul 27, 2018 | 3:27 PM GMT

FDA approved Nivestym filgrastim-aafi from Pfizer Inc. (NYSE:PFE), its biosimilar version of neutropenia drug Neupogen

Read the full 159 word article

How to gain access

Continue reading with a
two-week free trial.